Clinical Trials Logo

Hearing Loss clinical trials

View clinical trials related to Hearing Loss.

Filter by:

NCT ID: NCT01611129 Completed - Clinical trials for Disability Evaluation

Internet-based Pre-fitting Counseling of Persons With Hearing Impairment

Start date: November 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the use of 'patient journey' model in internet-based counseling of a person with hearing impairment is a feasible approach in management of emotional and social consequences, anxiety and depression, readiness to change and acceptance of hearing loss.

NCT ID: NCT01588925 Completed - Hearing Loss Clinical Trials

Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation

Start date: November 2011
Phase: Phase 2
Study type: Interventional

The objective of the present study is to investigate the effect dexamethasone and hyaluronic acid have on hearing preservation

NCT ID: NCT01532713 Completed - Clinical trials for SSNHL(Sudden Sensory Neural Hearing Loss)

The Effect of Oxygen Administration on Regional Cerebral Oxygen Saturation (rSO2) in the Non-block Side After Stellate Ganglion Block

Start date: January 2012
Phase: N/A
Study type: Interventional

Stellate ganglion block (SGB) is known to increase blood flow to the innervation area of the stellate ganglion. Near infrared spectroscopy reflects changes of blood volume and allows continuous, non-invasive, and bedside monitoring of regional cerebral oxygen saturation (rSO2). Previous studies have shown the increment of the rSO2 on the block side from the baseline and the decrement of the rSO2 on the non-block side after SGB. Patients with cerebral vascular disease undergoing SGB might be at risk a decrease in cerebral blood flow in the non-block side. The investigators researched the effect of oxygen administration on rSO2 in the non-block side using a near infrared spectroscopy after SGB. 5 L/min oxygen was supplied via nasal cannula from 15 minutes after SGB. The rSO2 in the non-block side were measured before SGB and 5, 10, 15, 20, 25 and 30 minutes after SGB. The present study suggests that oxygen administration can increase the rSO2 of non-block side. In conclusion, it is our belief that oxygen supplement is helpful to the patient with cerebral vascular disease during SGB.

NCT ID: NCT01518920 Completed - Clinical trials for Hearing Loss, Sensorineural

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Start date: December 2011
Phase: Phase 1
Study type: Interventional

The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

NCT ID: NCT01454895 Completed - Clinical trials for Noise-induced Hearing Loss

Test of a Web-based Intervention to Promote Hearing Protector Use

Start date: November 2011
Phase: N/A
Study type: Interventional

The purpose of this project is to compare the effectiveness of several approaches to influencing hearing protector use. The goals of this study are to further develop an intervention to promote farmers' use of hearing protectors, and compare the effectiveness of the developed intervention with two alternative approaches to influencing hearing protector use behavior, delivered in various combinations. This study will determine if significant change in hearing protection use can be achieved in a one-shot web-based or protector-supply intervention. Results will determine the need for future program modifications, e.g., inclusion of booster(s).

NCT ID: NCT01452607 Completed - Cancer Clinical Trials

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Start date: May 2006
Phase: Phase 1
Study type: Interventional

A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.

NCT ID: NCT01434446 Completed - Clinical trials for Sensorineural Hearing Loss

The Effect of Sound Stimulation on Hearing Ability

Start date: September 2011
Phase: N/A
Study type: Interventional

In the late 1990s, researchers discovered that acoustic stimuli slow progressive sensorineural hearing loss and exposure to a moderately augmented acoustic environment can delay the loss of auditory function. In addition, prolonged exposure to an augmented acoustic environment could improve age-related auditory changes. These ameliorative effects were shown in several types of mouse strains, as long as the acoustic environment was provided prior to the occurrence of severe hearing loss. In addition to delaying progressive hearing loss, acoustic stimuli could also protect hearing ability against damage by traumatic noise. In particular, a method called forward sound conditioning (i.e., prior exposure to moderate levels of sound) has been shown to reduce noise-induced hearing impairment in a number of mammalian species, including humans. Interestingly, recent report has suggested that low-level sound conditioning also reduces free radical-induced damage to hair cells, increases antioxidant enzyme activity, and reduces Cox-2 expression in cochlea, and can enhance cochlear sensitivity. Specifically, increased cochlear sensitivity was observed when distortion product otoacoustic emissions (DPOAEs) and compound action potentials (CAPs) were measured. In addition to forward sound conditioning, backward sound conditioning (i.e., the use of acoustic stimuli after exposure to a traumatic noise) has been shown to protect hearing ability against acoustic trauma and to prevent the cortical map reorganization induced by traumatic noise. In this study, the investigators examine the effect of sound stimulation on hearing ability in human subjects.

NCT ID: NCT01408992 Completed - Hearing Loss Clinical Trials

Thai-version Five Minute Hearing Test

Thai_FMHT
Start date: July 2011
Phase: N/A
Study type: Interventional

This study is aimed to test the sensitivity and specificity of Thai-version Five Minutes Hearing test against the audiometry to screen hearing problem in community.

NCT ID: NCT01400178 Completed - Deafness Clinical Trials

Cochlear Implants in Post-lingually Children: Results After 10 Years

Start date: November 2009
Phase: N/A
Study type: Observational

Objectives: To assess a group of post-lingually children after 10 years of implantation with regard to speech perception, speech intelligibility, and academic/occupational status. Study Design: A prospective transversal study. Setting: Pediatric referral center for cochlear implantation. Patients: Ten post-lingually deafened children with Nucleus and Med-El cochlear implants. Interventions: Speech perception and speech intelligibility tests and interview. Main Outcome Measures: The main outcome measures were score of Hint sentences recognition (silence and noise), speech intelligibility scores(write-down intelligibility and rating scale scores) and academic/ occupational status.

NCT ID: NCT01372904 Completed - Clinical trials for Cisplatin Ototoxicity

Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment

Start date: June 2011
Phase: Phase 4
Study type: Interventional

Cisplatin is a widely used chemotherapeutic agent for the treatment of various malignant neoplasms, including testicular, ovarian, bladder, cervix uteri, head and neck and lung cancers. One of the common side-effects of this drug is bilateral, symmetric, progressive and usually irreversible sensorineural hearing loss. Cisplatin induces cochlear toxicity by the production of reactive oxygen species (ROS). Dexamethasone treatment is currently practiced for various pathologies afflicting the inner ear. The positive effect of Dexamethasone is attributed to it's anti ROS activity and it's capability to up-regulate cochlear anti ROS enzymes. In order to reach higher inner ear concentration of the drug while avoiding it's undesirable systemic side-effects, Intratympanic (IT) delivery of Dexamethasone became vastly used in the last decades for the treatment of sudden sensorineural hearing loss and Meniere's disease. Dexamethasone inserted IT, diffuse across the round window into the inner ear perilymph where it exerts its therapeutic effects. The investigators review of the literature yielded three animal studies which examined the protective effect of IT dexamethasone in the prevention of cisplatin-induced hearing loss. These studies demonstrated promising results pointing to the potential for IT dexamethasone in the prevention of cisplatin ototoxicity in humans. The purpose of this study is to examine possible protective effect of IT dexamethasone on cisplatin-induced hearing loss, in humans. The study hypothesis is that IT dexamethasone treatment would prevent cisplatin-induced hearing loss.